TSE:TF

Timbercreek Financial (TF.TO)

6.55
+0.02 (0.31%)
as of Jul 10, 2026, 8:00:00 pm Market Open.
108 watching
0
Investor Insights
star iconJul 10, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Timbercreek Financial (TF-T) has faced challenges, experiencing a decline over the past five years. Despite this, experts highlight the potential for a future turnaround, especially for those knowledgeable about the company. The stock is primarily involved in short-term mortgages, where it generates income from these investments. Its recent performance was impacted by market sentiment relating to the commercial and residential real estate sectors, leading to its current undervaluation compared to its net asset value. With a solid dividend yield, albeit riskier due to its high percentage, patience may reward investors with capital gains in the long run.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
SII
TOP PICK

Short term lending. One of the best managers of buying and servicing mortgages. Incredibly stable. 6% yield. Well diversified. Strong management.

COMMENT

Timbercreek Mortgage (TMC-T). Invests in short-term loans, 9-18 months. If you own, you have to stay on top of the portfolio Because it turns over relatively quickly. 9% yield.

BUY

Mortgage investment. Good, stable cash flow. Yield of about 9%. The average term on their mortgages is 8-12 months. Construction and short-term financing. Good management. Strictly a yield play for him and he is not looking for capital appreciation.

DON'T BUY

At the bottom end of his database. Reported 9% negative earnings. Last $.35 in 2006. Great technology, but it seems to be taking forever to get it out into the marketplace.

BUY

This stock is at the bottome 15% of the database. Long on promise short on delivery type of company. They have tests for Avian flu and genetic tests for newborns. Signed up a large number of testing facilities in the U.S, but this is only used in a small range. He has owned in the past but does not own currently. If Avian flu passes to humans this company would benefit.

DON'T BUY

Quest (DGX-N) has done a "toe-in-the-water" on their product giving them a limited exposure to it. Was the product successful and will Quest and others broaden out their purchases? Very interesting product. Ranks poorly in his overall model at this point.

WEAK BUY

Speculative. Good technology. Less expensive technologies.

BUY

Very volatile. Have a tiny percentage in a couple of their funds. Have superior technology in genetic testing. An early stage company. Should see breakeven by the end of the year.

BUY

Trades in a band of $.40 to $.50. They have a methodology which should be quite powerful for them in 2004. Have a one-year lead over Pfizer. Speculative but pretty good prospects.

BUY

Profitable. Good product.

BUY ON WEAKNESS

In a good area Too speculative Watch for new clients

Showing 31 to 41 of 41 entries